admin – eisai china lnc.-开元体育官网下载手机版

 admin – eisai china lnc.-开元体育官网下载手机版

entries by

leqembi® (lecanemab) authorized for early alzheimer’s disease in great britain

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that the humanized amyloid-beta (aβ) monoclonal antibody “leqembi®” (brand name, generic name: lecanemab) has been granted a marketing authorization by the medicines and healthcare products regulatory agency (mhra) in great […]

eisai and biogen announced today that eisai has initiated the rolling submission of a biologics license application (bla) to the u.s. food and drug administration (fda) for lecanemab-irmb (u.s. brand name: leqembi®) subcutaneous autoinjector for weekly maintenance dosing after it was granted fast track designation by the fda.

,

eisai co., ltd. announced on jan 26 that it has submitted a new drug applicationfor ultrahigh-dose mecobalamin (development code: e0302) for the indication of amyotrophic lateral sclerosis (als) to the pharmaceuticals and medical devices agency in japan.

网站地图